Poster Abstract Session:
202. Novel Antimicrobial Agents
Saturday, October 20, 2012: 12:30 PM-2:00 PM
Room: SDCC Poster Hall F-H

Topical Category: A. Antimicrobial Agents

Tracks: Adult ID, Investigative ID


Evaluation of RPX2003 alone and in combination with RPX7009, a serine beta-lactamase inhibitor (BLI), against P. aeruginosa (PSA)
Mojgan Sabet, PhD ; Paula King, MPH ; Ziad Tarazi, BS ; Donxu Sun, PhD ; David Griffith, BS ; Olga Lomovskaya, PhD ; Michael Dudley, PharmD, FIDSA

A Novel Macrolide/Fluoroketolide, Solithromycin Exerts Superior Anti-inflammatory Effect via NF-κB Inhibition in COPD Cells
Kazuhiro Ito, PhD ; Yoshiki Kobayashi, PD/MD ; Hiroo Wada ; Peter J. Barnes ; Prabhavathi Fernandes, PhD

Solithromycin (CEM-101) Displays High Antimicrobial Activity Against Extracellular and Intracellular Neisseria gonorrhoeae
Julia Mallegol, PhD ; Prabhavathi Fernandes, PhD ; Christine Seah ; Cyril Guyard, PhD ; Roberto Melano, PhD

In Vitro Activity of Ceftolozane/Tazobactam (CXA-201) versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals: CANWARD 2011
Andrew Walkty, MD ; Melanie Baxter, MSc ; Heather J. Adam, PhD ; Kim Nichol, MSc ; Philippe Lagacé-Wiens ; James Karlowsky, PhD ; Daryl Hoban, PhD ; George G. Zhanel, PhD

A Novel Treatment for Onychomycosis in HIV-infected Persons: Vicks VapoRubTM, Both Effective and Safe
Mariea Snell, MSN, FNP-BC ; Sara Hubert, MSW ; Mike Klebert, PhD ; Warren Seyfried, PhD ; Nur Onen, BSc, MBChB

The Pharmacokinetic Interactions of HCV Protease Inhibitor TMC435 With Antiretroviral Agents in Healthy Volunteers
Sivi Ouwerkerk-Mahadevan ; Vanitha Sekar, PhD ; Alexandru Simion ; Monika Peeters ; Maria Beumont-Mauviel, MD

Response to imipenem plus MK-7655, a novel beta-lactamase inhibitor, among 212 recent clinical isolates of P. aeruginosa
Katherine Young, MS ; Meredith Hackel, PhD, MPH ; Christine Lascols, MS ; Samuel Bouchillon, MD ; Robert Badal, B.S. ; Luis Martínez-Martínez ; Chris Pillar, PhD ; Dean Shinabarger, PhD ; Jennifer Deane ; Dan Sahm

Novel Antimicrobial Block Copolypeptides for the Prevention and Treatment of Local Infections
Janet Chow, Ph.D. ; Jarrod Hanson, Ph.D. ; Diego Benitez, Ph.D. ; Kevin Ogilby, B.S. ; Michael Bevilacqua, M.D., Ph.D.

Unique Physical Properties of Synthetic Antimicrobial Block Copolypeptides Designed for Wound Infections
Jarrod Hanson, Ph.D. ; Ekaterina Tkatchouk, Ph.D. ; Evan Schauer, M.S. ; Kevin Ogilby, B.S. ; Janet Chow, Ph.D. ; Diego Benitez, Ph.D. ; Michael Bevilacqua, M.D., Ph.D.

A Study to Assess Skin Lesion Measurement Techniques Related to Acute Bacterial Skin and Skin Structure Infections
Michael Dunne, MD ; Purvi Mehra, MD ; Sinikka Green, MD ; Wade Sears, MD ; Robert Cockrell ; Paul Manos, DO ; George Talbot, MD ; Anita Das, PhD
  • Poster 1624_IDSA 2012_FINAL.pdf (569.6 kB)

  • A Barrier-Forming Oral Formulation Containing Cetylpyridinium Chloride (fCPC) Reduces Oral Microbial Load in Healthy Individuals Over a Five-Day Treatment Period
    Mahmoud Ghannoum, PhD ; Pranab Mukherjee, PhD ; Richard Jurevic ; Jyostna Chandra, PhD ; Frank Esper, MD ; Afif Ghannoum ; Brian Sokol ; Robert Salata, MD

    Safety, Tolerability and Pharmacokinetics (PK) of Intravenous Zanamivir (IVZ) Treatment in Hospitalized Adults with Influenza: A Phase 2 Open-Label, Multicenter, Single Arm Study
    Visanu Thamlikitkul, MD ; Francisco Marty, MD ; Choy Man, BSc ; Henry Zhao, PhD ; Stephen Weller, MS ; Phillip Yates, PhD ; Charles van der Horst, MD ; Denis Garot, MD ; Bruno Francois, MD ; Michael Parry, MD ; Raphael Manez, MD ; Erica Bullock, BA ; Amanda Peppercorn, MD

    CME Credits:

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.